Slingshot members are tracking this event:

Bridgebio's (BBIO) Infigratinib (BBP-831) in Cholangiocarcinoma PDUFA date Estimated for June 1, 2021, based on 6-month timeline

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
BBIO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bbp-831, Infigratinib, Cholangiocarcinoma